John P. Cunha

What Is Otarmeni? Otarmeni (lunsotogene parvec-cwha) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency greater than 90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear. What Are Side Effects of Otarmeni?

Description for Idvynso IDVYNSO is a fixed-dose combination tablet for oral administration containing doravirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), and islatravir, an HIV-1 nucleoside analog reverse transcriptase inhibitor (NRTI). Each film-coated tablet contains 100 mg of doravirine and 0.25 mg islatravir as active ingredients.

Market overview The most immediate theme shaping the M&A landscape in Kuwait is the geopolitical climate in the Middle East. Tensions have eased somewhat at the time of writing, but the overall environment remains fragile and continues to influence investor sentiment and deal execution.